Recombinant Anti-PRSS8 antibody [EPR15327] (ab185236)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR15327] to PRSS8
- Suitable for: WB, IP
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-PRSS8 antibody [EPR15327]
See all PRSS8 primary antibodies -
Description
Rabbit monoclonal [EPR15327] to PRSS8 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- LnCAP and MCF7 cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR15327 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab185236 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 40 kDa (predicted molecular weight: 36 kDa).
|
|
IP |
1/40 - 1/60.
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 40 kDa (predicted molecular weight: 36 kDa). |
IP
1/40 - 1/60. |
Target
-
Function
Possesses a trypsin-like cleavage specificity. -
Tissue specificity
Found in prostate, liver, salivary gland, kidney, lung, pancreas, colon, bronchus and renal proximal tubular cells. In the prostate gland it may be synthesized in epithelial cells, secreted into the ducts, and excreted into the seminal fluid. -
Sequence similarities
Belongs to the peptidase S1 family.
Contains 1 peptidase S1 domain. -
Cellular localization
Cell membrane and Secreted > extracellular space. Found in the seminal fluid. Secreted after cleavage of its C-terminus. - Information by UniProt
-
Database links
- Entrez Gene: 5652 Human
- Entrez Gene: 76560 Mouse
- Omim: 600823 Human
- SwissProt: Q16651 Human
- SwissProt: Q9ESD1 Mouse
- Unigene: 75799 Human
- Unigene: 5875 Mouse
-
Alternative names
- 2410039E18Rik antibody
- AI313909 antibody
- C79772 antibody
see all
Images
-
Western blot analysis of immunoprecipitation pellet from MCF7 cell lysate, immunoprecipitated using ab185235 at 1/50 dilution (lane 1) or PBS control (lane 2).
Secondary: Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1500 dilution. -
All lanes : Anti-PRSS8 antibody [EPR15327] (ab185236) at 1/10000 dilution
Lane 1 : LnCAP cell lysate
Lane 2 : MCF7 cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 36 kDa
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (1)
ab185236 has been referenced in 1 publication.
- Cai C et al. Knocking down Sterol regulatory element binding protein 2 (SREBF2) inhibits the Serine Protease 8 (PRSS8) /sodium channel epithelial 1alpha subunit (SCNN1A) axis to reduce the cell proliferation, migration and epithelial-mesenchymal transformation of ovarian cancer. Bioengineered 12:9390-9400 (2021). PubMed: 34823420